Monarch Therapeutics and SNAP Biosciences, Inc., a Subsidiary of Coeptis Therapeutics Holdings Inc., Enter Licensing Agreement to Bolster SNAP-CAR NK Cell Therapy in Oncology
SNAP Biosciences, a subsidiary of Coeptis Therapeutics Holdings (NASDAQ: COEP), has entered into a licensing agreement with Monarch Therapeutics to enhance their SNAP-CAR NK cell therapy platform in oncology. The agreement provides SNAP Biosciences access to Monarch's small molecule adaptor technology, which enables SNAP-CAR cells to be directed by small molecule-based adaptors.
The integration of Monarch's technology with SNAP-CAR NK cells allows for simultaneous targeting of multiple tumor antigens and real-time activity modulation, addressing challenges like tumor heterogeneity and antigen escape. Under the agreement terms, Monarch will receive an upfront payment, potential development milestone payments, and royalties on net sales.
SNAP Biosciences, una controllata di Coeptis Therapeutics Holdings (NASDAQ: COEP), ha siglato un accordo di licenza con Monarch Therapeutics per migliorare la loro piattaforma di terapia cellulare SNAP-CAR NK in oncologia. L'accordo consente a SNAP Biosciences di accedere alla tecnologia di adattatori a piccole molecole di Monarch, che permette di indirizzare le cellule SNAP-CAR tramite adattatori basati su piccole molecole.
L'integrazione della tecnologia di Monarch con le cellule SNAP-CAR NK consente di colpire contemporaneamente più antigeni tumorali e di modulare l'attività in tempo reale, affrontando problematiche come l'eterogeneità tumorale e la fuga antigenica. Secondo i termini dell'accordo, Monarch riceverà un pagamento iniziale, potenziali pagamenti legati a milestone di sviluppo e royalties sulle vendite nette.
SNAP Biosciences, una subsidiaria de Coeptis Therapeutics Holdings (NASDAQ: COEP), ha firmado un acuerdo de licencia con Monarch Therapeutics para mejorar su plataforma de terapia celular SNAP-CAR NK en oncología. El acuerdo otorga a SNAP Biosciences acceso a la tecnología de adaptadores de pequeñas moléculas de Monarch, que permite dirigir las células SNAP-CAR mediante adaptadores basados en pequeñas moléculas.
La integración de la tecnología de Monarch con las células SNAP-CAR NK permite atacar simultáneamente múltiples antígenos tumorales y modular la actividad en tiempo real, abordando desafíos como la heterogeneidad tumoral y la evasión antigénica. Según los términos del acuerdo, Monarch recibirá un pago inicial, posibles pagos por hitos de desarrollo y regalías sobre las ventas netas.
SNAP Biosciences는 Coeptis Therapeutics Holdings (NASDAQ: COEP)의 자회사로서, 종양학 분야의 SNAP-CAR NK 세포 치료 플랫폼을 강화하기 위해 Monarch Therapeutics와 라이선스 계약을 체결했습니다. 이 계약을 통해 SNAP Biosciences는 Monarch의 소분자 어댑터 기술을 활용할 수 있게 되었으며, 이를 통해 SNAP-CAR 세포를 소분자 기반 어댑터로 조절할 수 있습니다.
Monarch의 기술과 SNAP-CAR NK 세포의 통합은 다중 종양 항원을 동시에 표적화하고 실시간으로 활동을 조절할 수 있게 하여, 종양 이질성과 항원 회피 같은 문제를 해결합니다. 계약 조건에 따라 Monarch는 선급금, 개발 마일스톤에 따른 잠재적 지급금, 순매출에 대한 로열티를 받게 됩니다.
SNAP Biosciences, une filiale de Coeptis Therapeutics Holdings (NASDAQ : COEP), a conclu un accord de licence avec Monarch Therapeutics afin d'améliorer leur plateforme de thérapie cellulaire SNAP-CAR NK en oncologie. Cet accord permet à SNAP Biosciences d'accéder à la technologie d'adaptateurs à petites molécules de Monarch, qui permet de diriger les cellules SNAP-CAR grâce à des adaptateurs basés sur de petites molécules.
L'intégration de la technologie de Monarch avec les cellules SNAP-CAR NK permet de cibler simultanément plusieurs antigènes tumoraux et de moduler l'activité en temps réel, répondant ainsi aux défis tels que l'hétérogénéité tumorale et l'échappement antigénique. Selon les termes de l'accord, Monarch recevra un paiement initial, des paiements potentiels liés à des jalons de développement, ainsi que des redevances sur les ventes nettes.
SNAP Biosciences, eine Tochtergesellschaft von Coeptis Therapeutics Holdings (NASDAQ: COEP), hat eine Lizenzvereinbarung mit Monarch Therapeutics geschlossen, um ihre SNAP-CAR NK-Zelltherapieplattform im Bereich Onkologie zu verbessern. Die Vereinbarung gewährt SNAP Biosciences Zugang zu Monarchs Technologie für kleine Molekül-Adapter, die es ermöglicht, SNAP-CAR-Zellen mittels kleiner molekularer Adapter zu steuern.
Die Integration der Monarch-Technologie mit SNAP-CAR NK-Zellen erlaubt die gleichzeitige Zielausrichtung auf mehrere Tumorantigene und die Echtzeitmodulation der Aktivität, wodurch Herausforderungen wie Tumorheterogenität und Antigenflucht adressiert werden. Gemäß den Vertragsbedingungen erhält Monarch eine Vorauszahlung, potenzielle Entwicklungsmeilensteinzahlungen sowie Lizenzgebühren auf den Nettoumsatz.
- Access to Monarch's innovative small molecule adaptor technology enhances SNAP-CAR NK cell therapy precision and flexibility
- Technology enables simultaneous targeting of multiple tumor antigens and real-time activity modulation
- Improved manufacturing and regulatory pathway for NK cell therapies
- Potential to address tumor heterogeneity and antigen escape challenges
- Financial terms and upfront payment amounts not disclosed
- Timeline for development and commercialization not specified
- Future milestone payments and royalties dependent on successful development
Insights
Coeptis gains access to Monarch's adaptor technology to enhance its SNAP-CAR NK cell therapy platform, potentially creating more effective cancer treatments.
This licensing agreement represents a strategic enhancement to Coeptis Therapeutics Holdings' cell therapy capabilities through its SNAP Biosciences subsidiary. The deal gives SNAP access to Monarch's small molecule adaptor technology to bolster their proprietary Snap-Car NK cell therapy platform in oncology.
The technical significance lies in how this integration allows SNAP-CAR NK cells to be directed by small molecule-based adaptors, potentially solving several critical challenges in current cell therapies. The combined technology platform should enable:
- Simultaneous targeting of multiple tumor antigens
- Real-time modulation of therapeutic activity
- Improved manufacturing and regulatory pathways
- Better management of tumor heterogeneity
- Reduced risk of antigen escape mechanisms
From a financial perspective, Monarch receives an upfront payment of undisclosed size, plus eligibility for
This partnership aligns with the broader industry trend toward modular, adaptable cell therapy platforms rather than single-target approaches. The emphasis on NK (natural killer) cells rather than T-cells is also noteworthy, as NK cell therapies potentially offer advantages in safety profile and manufacturing simplicity compared to CAR-T approaches.
While promising, investors should note this remains an early-stage technology partnership with typical development timelines measured in years before potential commercialization or revenue generation.
WEXFORD, Pa. and PRINCETON, N.J., May 28, 2025 (GLOBE NEWSWIRE) -- SNAP Biosciences, Inc a majority-owned subsidiary of Coeptis Therapeutics Holdings Inc. (Nasdaq: COEP) and Monarch Therapeutics Inc., a biotechnology company pioneering next-generation immunotherapies, today announced a licensing agreement to enable the development and commercialization of SNAP Biosciences’ proprietary Snap-Car NK cell therapy platform in oncology using Monarch’s small molecule adaptor technology.
This agreement grants SNAP Biosciences access to Monarch’s novel small-molecule adaptor-based technology platform, significantly broadening the functionality of the Snap-Car universal CAR-based receptor platform. Monarch’s ground-breaking small molecule approach, invented by Monarch’s scientific co-founders Drs. Jason Lohmueller and Alexander Deiters, enables SNAP-CAR cells to be directed by small molecule-based adaptors, enhancing the system’s precision, flexibility, and modular potential across diverse therapeutic areas.
“This agreement underscores the growing recognition of our adaptor technology as a transformative tool for cell therapy,” said Christopher Potts, CEO of Monarch Therapeutics. “We are thrilled to have the team at SNAP Bioscience bring this exciting technology to patients with a new generation of NK therapies that have the potential to be both highly targeted and curative.”
The Snap-Car NK cells represent a promising platform technology in the cell therapy landscape. By integrating Monarch’s small molecule adaptors, these therapies can now be engineered to simultaneously target multiple tumor antigens and modulate their activity in real-time, with an improved manufacturing and regulatory pathway. This advanced functionality offers a significant leap forward in addressing tumor heterogeneity and challenges associated with antigen escape commonly encountered in oncology.
“We are thrilled to incorporate this innovative adaptor technology into our Snap-Car NK platform,” said Dave Mehalick, CEO at Coeptis Therapeutics Holdings, inc. “This collaboration positions us to advance more potent, flexible, and scalable NK therapies aimed at transforming outcomes for patients with difficult-to-treat cancers.”
Under the terms of the agreement, Monarch will receive an upfront licensing payment and is eligible for future development milestone payments, as well as royalties on net sales.
About Monarch Therapeutics Inc.
Monarch Therapeutics is a pre-clinical stage biotechnology company focused on developing next-generation immunotherapies. The company’s proprietary adaptor platform enables precise, programmable control of cell-based therapies, expanding their reach and dynamic disease targeting across a broad range of therapeutic areas. With a focus on solid tumors, Monarch Therapeutics implements its adaptor platform to drive universal CAR-T cell therapies with leading tunability, mutli-antigen targeting, and control. For more information, visit https://monarchtherapeutics.com/
About SNAP Biosciences Inc.
SNAP Biosciences, Inc is a majority-owned subsidiary and one of the biopharmaceutical divisions of Coeptis Therapeutics Holdings, Inc. SNAP Bioscience’s is focusing on the development of Snap-Car, a "universal" CAR (chimeric antigen receptor) cell therapy, that uses a SNAP molecule to connect a CAR to tumor cells. This allows for programmable antigen targeting through co-administered antibodies, providing flexibility in targeting multiple antigens and indications. For more information, visit https://snapbioscience.com
About Coeptis Therapeutics Holdings, Inc
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Technologies (collectively "Coeptis"), is a biopharmaceutical and technology company. The biopharmaceutical divisions focus on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
Coeptis’ therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Coeptis is also developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), alongside GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers at the Karolinska Institute.
Building on its core competencies, Coeptis has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in Wexford, PA, Coeptis is dedicated to advancing its mission within the regulatory framework set forth by the Food and Drug Administration, ensuring that all activities align with the highest standards of compliance and patient care. For more information on Coeptis and its lines of business, visit https://coeptistx.com
Contacts
IR@coeptistx.com
FAQ
What is the significance of COEP's licensing agreement with Monarch Therapeutics?
How does Monarch's technology improve SNAP-CAR NK cell therapy?
What are the financial terms of COEP's licensing agreement with Monarch?
What therapeutic areas will COEP's enhanced SNAP-CAR NK cell therapy target?
Who developed Monarch's small molecule adaptor technology?
